Leukemia Research
Volume 27, Issue 7 , Pages 617-626 , July 2003

Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines

  • Michael Pearlman

      Affiliations

    • Departments of Leukemia and Special Medical Education Programs, M.D. Anderson Cancer Center, Unit 55, The University of Texas, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    • ,
  • David Jendiroba

      Affiliations

    • Departments of Leukemia and Special Medical Education Programs, M.D. Anderson Cancer Center, Unit 55, The University of Texas, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    • ,
  • Lance Pagliaro

      Affiliations

    • Department of Genitourinary Oncology, M.D. Anderson Cancer Center, Unit 427, The University of Texas, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    • ,
  • Afsaneh Keyhani

      Affiliations

    • Departments of Leukemia and Special Medical Education Programs, M.D. Anderson Cancer Center, Unit 55, The University of Texas, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    • ,
  • Baoshun Liu

      Affiliations

    • Departments of Leukemia and Special Medical Education Programs, M.D. Anderson Cancer Center, Unit 55, The University of Texas, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    • ,
  • Emil J Freireich

      Affiliations

    • Departments of Leukemia and Special Medical Education Programs, M.D. Anderson Cancer Center, Unit 55, The University of Texas, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-713-792-2660; fax: +1-713-794-1812.

Received 11 June 2002 ,Accepted 10 October 2002.

References 

  1. Jemal A, Thomas A, Murray T, Thun M. Cancer Statistics, 2002. CA Cancer J. Clin. 2002;52(1):23–47
  2. Neglia J. Epidemiology of childhood acute leukemias. Pediatr. Clin. North Am. 1988;35:675–692
  3. Freireich EJ. Acute leukemia: a prototype of dissemintaed cancer. Cancer. 1984;53:2026–2033
  4. Pharmacia. Pharmacia investigators’ brochure for Zinecard (dexrazoxane). 1996.
  5. Koeller JM, Earhart RH, Davis HL. Phase I trial of ICRF-187 by 48-h continuous infusion. Cancer Treat. Rep. 1981;65(5/6):459–463
  6. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr. Med. Chem. 1998;5(1):1–28
  7. Nara N. The proliferation in suspension of the progenitors of the blast cells in acute myeloblastic leukemia. Blood. 1985;65:1484–1493
  8. Buick R. Colony assay proliferative blast cells circulating in myeloblastic leukemia. Lancet. 1977;1:862–863
  9. Chou T. Quantitiative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984;22:27–55
  10. Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin. Oncol. 1998;25:10–21
  11. Eliot H. Oxidative destruction of DNA by the adriamycin–iron complex. Biochemistry. 1984;23:928
  12. Batist G. Cardiac and red blood cell glutathione peroxidase: results of a prospective randomized trial in patients on total parental nutrition. Cancer Res. 1985;45:5900–5903
  13. Muindi J. hydroxyl radical production and DNA damage induced by anthracycline–iron complex. FEBS Lett. 1984;172:226–230
  14. Muindi J, Sinha BK, Gianni L, Myers C. Thiol-dependent DNA damage produced by anthracycline–iron complexes: the structure–activity relationships and molecular mechanisms. Mol. Pharmacol. 1985;27:356–365
  15. Myers C. Oxidative damage of erythrocyte ghost membranes catalyzed by the doxorubicin–iron complex. Biochemistry. 1982;21:1707–1712
  16. Myers C. Anthracyclines. Cancer Chemother. 1986;8:52–64
  17. Myers CE, Muindi JR, Zweier J, Sinha BK. 5-Iminodaunomycin. An anthracycline with unique properties. J. Biol. Chem. 1987;262:11571–11577
  18. Zweier JL, Gianni L, Muindi J, Myers CE. Differences in O2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group. Biochim. Biophys. Acta. 1986;884:326–336
  19. Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 1988;48(17):4766–4769
  20. Hasinoff BB, Yalowich JC, Ling Y, Buss JL. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs. 1996;7(5):558–567
  21. Holm B, Jensen PB, Sehested M. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother. Pharmacol. 1996;38(3):203–209
  22. Hellmann K. Overview and historical development of dexrazoxane. Semin. Oncol. 1998;25(4 Suppl 10):48–54
  23. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J. Clin. Oncol. 1997;15(4):1333–1340
  24. Budman DR, Calabro A, Kreis W. In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?. Leukemia. 2001;15:1517–1520
  25. Wadler S, Green MD, Muggia FM. Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (Icrf 187) against the murine sarcoma S180 cell line. Cancer Res. 1986;46(3):1176–1181
  26. Monti E, Sinha BK. Potentiation of doxorubicin cytotoxicity by (+)-1,2-bis-(3,5-dioxopiperazinyl-1-yl) propane (Icrf-187) in human leukemic Hl-60 cells. Cancer Commun. 1990;2(4):145–149
  27. Scambia G, Della Bitta R, Benedetti Panici P, De Vincenzo R, Contu G, Ercoli A, et al. Bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells. Gynecol. Oncol. 1995;57(1):16–22
  28. Wang G, Finch MD, Trevan D, Hellmann K. Reduction of daunomycin toxicity by razoxane. Br. J. Cancer. 1981;43(6):871–877

PII: S0145-2126(02)00273-4

doi: 10.1016/S0145-2126(02)00273-4

Leukemia Research
Volume 27, Issue 7 , Pages 617-626 , July 2003

Article Tools

* Image Usage & Resolution